TY - JOUR
T1 - New strategies in peripheral T-cell lymphoma
T2 - Understanding tumor biology and developing novel therapies
AU - Dunleavy, Kieron
AU - Piekarz, Richard L.
AU - Zain, Jasmine
AU - Janik, John Edward
AU - Wilson, Wyndham H.
AU - O'Connor, Owen A.
AU - Bates, Susan E.
PY - 2010/12/1
Y1 - 2010/12/1
N2 - Peripheral T-cell lymphomas (PTCL) constitute a group of heterogeneous diseases that are uncommon, representing, in Western countries, only approximately 10% of all non-Hodgkin lymphomas. They are typically associated with a poor prognosis compared with their B-cell counterparts and are much less well understood with respect to tumor biology, owing to their rarity and biologic heterogeneity, and to the fact that characteristic cytogenetic abnormalities are few compared with B-cell lymphomas. Although the outcome for patients with anaplastic large cell lymphoma (ALCL), particularly anaplastic lymphoma kinase (ALK)-positive ALCL, is good, other types of PTCLs are associated with a poor prognosis, even with aggressive anthracycline-based chemotherapy. In this respect, there is a need for new approaches in these diseases, and this review focuses on and explores recent experience with novel therapies in PTCL.
AB - Peripheral T-cell lymphomas (PTCL) constitute a group of heterogeneous diseases that are uncommon, representing, in Western countries, only approximately 10% of all non-Hodgkin lymphomas. They are typically associated with a poor prognosis compared with their B-cell counterparts and are much less well understood with respect to tumor biology, owing to their rarity and biologic heterogeneity, and to the fact that characteristic cytogenetic abnormalities are few compared with B-cell lymphomas. Although the outcome for patients with anaplastic large cell lymphoma (ALCL), particularly anaplastic lymphoma kinase (ALK)-positive ALCL, is good, other types of PTCLs are associated with a poor prognosis, even with aggressive anthracycline-based chemotherapy. In this respect, there is a need for new approaches in these diseases, and this review focuses on and explores recent experience with novel therapies in PTCL.
UR - http://www.scopus.com/inward/record.url?scp=78650367372&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650367372&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-09-1995
DO - 10.1158/1078-0432.CCR-09-1995
M3 - Review article
C2 - 21138864
AN - SCOPUS:78650367372
SN - 1078-0432
VL - 16
SP - 5608
EP - 5617
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 23
ER -